Penumbra (NYSE:PEN) this week posted fourth-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates.
The Alameda, California-based company reported losses of -$24.6 million, or -66¢ per share, on sales of $204 million for the three months ended Dec. 31, 2021, for a sales growth of 22.24% compared with Q4 2020.
Earnings per share were 30¢ behind estimates on The Street, where analysts were looking for sales of $194.3 million.
“In the fourth quarter, we achieved record revenue in both our neuro and vascular businesses. Also, we started making progress toward our goal of building a safe and secure healthcare platform using immersive computing to help a significant number of patients,” CEO Adam Elsesser said during an earnings call.
Penumbra said it expects total revenue for 2022 to be in the range of $860 million to $875 million to represent 15% to 18% growth over 2021.
Shares in PEN were up 0.42% to $217.50 apiece in pre-market trading.
